Keeping Track: Yupelri Is Latest Novel Drug Approved, But Bad News For Biosimilars

The latest drug development news and highlights from our US FDA Performance Tracker.

Keeping Track Feature image

The novel drug approvals continue to rain down from the US FDA, with the agency's nod to Theravance Biopharma Inc. and Mylan NV's Yupelri (revefenacin) bringing the 2018 record-breaking total to 49.

Poseida Therapeutics Inc. picked up a regenerative medicine advanced therapy (RMAT) designation for its relapsed/refractory multiple myeloma treatment P-BCMA-101,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet